Khalid Islam, PhD
Khalid served as chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led the transition of the loss-making company to cash-flow positive and profitable. Under his leadership Defitelio (defibrotide) was granted marketing authorization in the EU and the company’s value increased from $25m to $1billion in a cash merger with Jazz Pharmaceuticals, plc. From 1999-2008, he was president and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised $300M in the IPO and follow-ons. From 1987-1999, he held various positions in HMR & MMD (now Sanofi-Aventis). From 1977-1987, he worked in academia at Imperial College (University of London) and at Milan University, where he was a contract professor. Khalid is a graduate of Chelsea College and received his PhD from Imperial College, University of London. He holds several patents and has published over 85 articles in leading journals. He is also on the editorial board of Current Drug Discovery and Technologies. Khalid is currently the chairman of Fennec (FRX.TO; North Carolina) and a member of the board of directors at Karolinska Development (KDEV.ST; Stockholm), Molmed (MLM.MI; Milan), and OxThera (Stockholm). He has previously been a member of the board of directors at Arpida AG (Basel and DC), Rheoscience AS (Copenhagen), PCovery AS (Copenhagen), Adenium AS (Copenhagen) and C10 Pharma AS (Oslo).
Claude Nicaise, MD
Claude is an established leader in clinical drug development and worldwide regulatory strategy with more than 30 years of experience in the pharmaceutical and biotechnology industry. After graduating in medicine from the Université Libre de Bruxelles he began working for Bristol-Myers Squibb becoming Director of Clinical Cancer Research; Executive Director of Infectious Diseases Clinical Research; Vice-President Worldwide Regulatory Science and Strategy Oncology, Infectious Disease and NeuroScience. During his tenure with BMS, Claude led the development and worldwide registration of compounds such as etoposide, ifosfamide, videx, reyatase, cefepime, tequin, abilify, Erbitux and dasatinib. Subsequently, he joined Alexion as Senior Vice President of Strategic development and Global Regulatory Affair in where he had a leadership role in completing the worldwide registration of Soliris and implementing its life-cycle management. Claude has authored over a hundred papers in peer-reviewed journals or abstracts at international meetings, and is a member of a number of professional societies. Currently, he is board member at Sarepta Therapeutics.
Karen Wagner, PhD
General Partner, Ysios Capital
Karen is a senior executive and entrepreneur with 20 years’ experience in the biopharmaceutical industry. Karen is General Partner at Ysios Capital and has a leading role in the investment team and the portfolio. Prior to joining Ysios in 2008, she was a Global Alliance Director for F. Hoffmann-La Roche in Basel, Switzerland. She joined Roche from GLYCART, a biotech company in the antibody engineering space, which was acquired by Roche in 2005. Karen has also worked as a consultant. In addition to Minoryx, she serves on the Boards of Aelix Therapeutics, Vivet Therapeutics and Xeltis. In recent years Karen has also been a board member of Kala (IPO on Nasdaq in 2017) and Cardoz. She holds a master’s degree in Molecular Biology and a PhD in Cell Biology.
José Antonio Mesa, MBA
Life Science director, Caixa Capital Risc
José Antonio specializes in investment in drug development and medical devices companies. He currently serves on the Board of Directors at Laboratoris Sanifit, ABAC Therapeutics, Proteodesign and iProteos among others. He has more than 10 years of experience in the analysis of investment opportunities and specializes in the early stage health sector companies. His experience began in the Department of Business Development at Genzyme. He later joined the Technology Portfolio team at Genoma España, a public sector foundation that promotes technology development, knowledge transfer and innovation in the biotechnology sector. Jose Antonio holds a degree in Biology (Genetics) and a Masters in Corporate Finance from the U. Complutense, Madrid (UCM), MBA and PDD from IESE Business School.
Thierry Laugel, PhD MBA
Managing Partner, Kurma Partners
Thierry started his career in industry in 1992 in Japan for Laboratoires Fournier as scientific representative, where he worked in collaboration with Grelan, a Takeda Group company. He then moved to Flamel Technologies as project director for Pharmaceutical R&D, after its IPO on Nasdaq. In 1998, he moved to the investment world, first at Caisse des Dépôts (CDC Innovation, then with the PharmaVent project), before moving to AGF Private Equity, where he supervised the healthcare team. Since 2009, Thierry Laugel is a founder and Managing Partner of Kurma Partners, and is currently the Chairman of its Management Board. Thierry is a Pharmacist, with a PhD in pharmacology, and an MBA from Insead.
Anja Harmeier, PhD MBA
Investment Manager, Roche Venture Fund
Anja is Investment Manager at the Roche Venture Fund, Roche’s CHF 500M corporate venture fund. Previously she held various positions at Roche early stage research and development in Neuroscience and Rare Diseases. Anja has a PhD in Neuroscience/ Biochemistry from the Free University Berlin and a MBA from IE Madrid.
Gery Lefebvre, MSc
Investment Manager, S.R.I.W.
Gery graduated in Business Administration from HEC-University of Liège and immediately started his career in trade finance with Atradius and later in corporate banking/M&A at HSBC Paris. In 2002, he obtained a postgraduate Master’s degree in Taxation from HEC-University of Liège. Following that, he moved to Albemarle Europe and to GSK Biologicals where he was responsible for treasury management and Working Capital Optimization. Between 2009 – 2014, Gery was the CFO of Belgian Advanced Technology Systems SA. In 2014, he joined S.R.I.W. and has now several non-executive memberships in biotechnology start-ups/spin-offs and companies that are active in the life sciences sector.
Philippe Monteyne, MD PhD
Philippe has held senior positions in SmithKline Beecham, GSK and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012. More recently, he served as Vice President R&D France at Sanofi until early 2015. Philippe is a board director of a number of biotechnology companies in Belgium, France and Spain. He was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), Brussels. He holds an M.D. degree and Ph.D. in viral immunology, both from the UCL, is a fully trained neurologist, and has also been trained in neuro-immunology at Pasteur Institute in Paris.
Marc Martinell, PhD
Co-Founder & Chief Executive Officer
Marc obtained a PhD in Chemistry from the University of Barcelona. He has broad experience in drug discovery and biotechnology through his participation at companies such as Crystax Pharmaceuticals and Oryzon Genomics where he managed several research projects and led the team in charge of target selection, structural biology, computational chemistry and hit ID through a fragment-based approach. At Oryzon, Marc actively contributed to the identification of the first-in-class inhibitors for the epigenetic target LSD1 currently in clinical studies. Marc is co-author of several patents and publications, and besides his activities in the technological field always had an entrepreneurial calling.